4 Can’t-Miss Opportunities That All Medtech Companies Need to Consider

Interview with Jonas Funk

Listen to the Episode

0:000:00

Listen to the Episode

0:000:00

About the Guest

Jonas Funk is a Managing Director and Partner in L.E.K. Consulting’s Chicago office. He has more than 15 years of experience at L.E.K. and has directed hundreds of consulting engagements, primarily focused on growth strategy and mergers and acquisitions support in the medtech and life sciences industries. He co-founded the Tokyo office and has assisted dozens of clients in developing their Asian strategies. He holds a Bachelor of Arts in Economics from Carleton College and his work in economics has been published in leading academic journals and national newspapers.

Interview Summary

According to a recent L.E.K. survey of hospital executives, 56% of the respondents haven taken steps to reduce medical device sales rep access to their facilities. In fact, the CEO of an Illinois hospital stated,

“We’re constantly trying to limit the sales reps…We want to see what they’re selling before they get a hold of a doctor who brings it in without our knowledge.”

At least one answer is obvious, right? Hospitals are clearly not looking for advice from medical device sales reps. So what solutions are they looking for? Here is what a Director of Purchasing at a Minnesota hospital wants:

“We would really like clinical outcomes data…For example, we want to know if a knee replacement that costs two times as much as a competitor’s knee is actually going to last double the time as the competitor’s model.”

In other words, hospitals want to understand the cost/benefit analysis for the medical devices they purchase. That’s one idea medtech companies need to embrace. But what are the other 3?

In this interview with Jonas Funk, Managing Director in L.E.K.’s Chicago office, we learn about the 4-step process that medical device companies should consider in light of the current healthcare environment. And by the way, if you want a copy of L.E.K.’s most recent survey of hospital executives, contact Jonas via email at j.funk@lek.com.

Key Highlights with Jonas Funk

  • What are the most pressing challenges that medtech executives are facing right now?

  • Overview of L.E.K.’s most recent strategic hospital priorities study. How was it conducted? Who was involved? Etc.

  • Are hospital administrators the new KOLs?

  • In the pursuit of customer excellence, what are the 4 key questions that medtech companies need to answer?

  • The 4-step process that medtech companies need to embrace.

  • What is the one concept that medtech companies need to implement now? And what is the one concept that medtech companies absolutely must have on their radar for the future?

Read the Interview with Jonas Funk

Scott Nelson: Hello everyone, it’s Scott Nelson, and welcome to another episode. For those of you who are new to the program, this is a show where I interview experienced medtech and medical device thought leaders in an effort to learn as much as possible and then hopefully implement one or two big takeaways. And today’s guest on the program is Jonas Funk, who is a Managing Director and Partner in LEK Consulting’s Chicago office. He has more than 15 years of experience in LEK and has directed hundreds of consulting engagements primarily focused on growth strategy and mergers and acquisitions support within the medtech and life sciences verticals. Jonas also co-founded the Tokyo office and has assisted dozens of clients in developing their Asian strategy. So, without further ado, welcome to the program, Jonas.

Jonas Funk: Great to be here, Scott. Thanks.

Scott Nelson: Okay. So, Jonas, let's start here. You have the opportunity to consult with, discuss with, and probably in a lot of cases present to a lot of medtech executives and decision-makers. So, in your opinion, what do you are the one or two most pressing challenges that those folks are facing right now?

Jonas Funk: Yeah. I think the biggest challenges that they face kind of relate to how to navigate some pretty substantial changes that are occurring in the healthcare industry, and particularly with respect to transforming their organizations to be successful medtechs going forward. Fundamentally, what we're seeing is a shift from the old fee-per-service world to a new world where outcomes are going to be much more important and costs are much more important, and the old model that medtechs were very successful with is not going to be as successful in the future. So, making great products and convincing clinicians to use them worked well for a long time, but given some of the macro changes that we're seeing, that model is very much changing, and the challenges that a lot of our clients are facing is how to essentially respond to those changes given that a lot of the historical focus and capabilities have been in kind of areas that might not be as well aligned with the success in the future.

Scott Nelson: Sure.

Jonas Funk: So that's probably the high-level summary of what’s keeping them up at night.

Scott Nelson: Got it, and we'll definitely get a chance to dig into some more details for sure. But you've been with LEK now for quite a few years. Before I ask you a little bit about your background in LEK in general, does it seem like now is just a more crazy time than it ever has been within sort of the healthcare space?

Jonas Funk: Yeah, I think that's right, and I think some of the changes are actually happening faster than the healthcare industry has been used to. So, it is kind of required for executives to be able to respond faster than I think was required in the past. So yeah, I think that's right. A lot of changes both from a reimbursement regulatory perspective are out there, but at the end of the day, it's hitting the manufacturers in very specific and important ways that I think they're collectively trying to get their heads around and respond to.

Scott Nelson: Got it. Okay, so we're definitely going to dive into the release of your 2013 Hospital Priorities Study, but before I ask you about that study and then some of the ramifications or outcomes that you uncovered in this most recent study, give me and the audience a little bit of an overview about your background and then also LEK in general.

Jonas Funk: Sure. So, I think you summarized my background pretty well. I've been doing this for about 15 years. I spend pretty much all of my time in what we call the medtech space and helping our medtech clients grow and develop strategies to grow. LEK is a global management consulting firm, about a thousand people worldwide, offices in 20-plus countries, and our hospital survey that you alluded to is our fourth annual hospital survey. So, we've done this four years in a row, and the goal of the study is to essentially get a good sense of what hospitals are thinking in terms of their purchasing patterns and their needs with respect to medtech companies. So, we've been surveying and monitoring those needs and perspectives for the last several years to get a kind of ongoing sense of what their wishes are, of their suppliers, as well as to get a better sense of how some of the industry changes are manifesting in the hospital’s mind.

Scott Nelson: Got it. Okay. I want to ask you a little bit more about how this particular study is conducted each year, but in regard to your background, if we have time I definitely want to ask you about your time in Asia because that's definitely interesting, so hopefully we'll have time for that. One question in regard to LEK, LEK’s Consulting Services, you span a lot of different verticals, it's not just medtech and life sciences, correct?

Jonas Funk: That's right, but in the US almost 50% of what we do is healthcare-related…

Scott Nelson: Okay. Okay.

Jonas Funk: Then within healthcare, we have sectors that are focused on the payers or the providers, biopharmaceutical companies, and then I'm focused on our medtech practice…

Scott Nelson: Okay.

Jonas Funk: …working with one of the big medical device and diagnostic players.

Scott Nelson: Got it. Okay. So, let's transition to the 2013 hospital study. Can you provide us with a little bit more detail in regard to how it's typically conducted, who's involved, and maybe more specifically, where are you getting the responses from in terms of the role at the hospital that a particular person would play? Then we'll segue sort of into some of the key outcomes of the study.

Jonas Funk: Yeah, of course. So, for the last four years, we've done it and it's been focused on hospital administrators versus clinicians. So, very intentionally we've been focusing on the administrators, and about 200 respondents to our survey across a representative mix of hospitals big and small, academic, non-academic, urban, rural, and so on and so forth. Of the respondents, about a hundred of those are C-Suite, so CEOs, CFOs, COOs, versus the other 50% that are kind of other administrators that are involved in the purchase decision-making process, so VPs of procurement, materials managers, and people basically in the purchasing functions at hospitals.

Scott Nelson: Got it. Okay. You mentioned that's an interesting sort of side note, but you touched on it just real briefly. These are responses not just from larger 500-plus-bed hospitals in major metropolitan cities. You're also getting responses from the outlying community hospitals as well?

Jonas Funk: That's right. That's right.

Scott Nelson: Got it.

Jonas Funk: It's intentionally a representative mix of the overall market.

Scott Nelson: Got it. Your hospital priority study, has always focused on administrators versus or in contrast to clinicians?

Jonas Funk: It has, although I think over the last year or two we're particularly, I’d say, glad that it's been focused on administrators because several years ago we saw the beginning of a trend for greater influence among the administrators in purchase decision-making, so with thought, it would be a good group to start surveying. Indeed, over the last several years, we're seeing a very pronounced trend for a greater, greater involvement and influence of the administrators in the decision-making process and their respective needs for more economic considerations, not just the clinical considerations that we've typically been used to among the clinician stakeholder groups that have been the primary call point targets for medtech companies for a long time.

Scott Nelson: Yeah. That's why I'm pretty anxious to get into the outcomes of this study and what it means for medtech and medical device companies. But I love the fact that it's administrator-focused because so many times the word KOL or key opinion leader, you know…

Jonas Funk: Right.

Scott Nelson: …within the medtech space is often thought of as the clinician or the physician, but more so now than ever it's going to be probably administrators within large health systems, or not just health systems but administrators in large hospitals as well that are…

Jonas Funk: Yeah.

Scott Nelson: …going to be considered KOLs, which is kind of an interesting concept if you've been entrenched in medtech for a while.

Jonas Funk: Yeah, I think that's generally right. I don’t want to overstate it. The clinicians, in particular, leading clinicians and key opinion leaders, and department heads certainly have a point of view that they will share that can be very influential in specific departments or for specific products. But the general trend that we're seeing is gradual migration from the clinician’s shoes as what product he or she uses to, at the minimum, a conversation or a value analysis committee decision that involves administrators where there's much more scrutiny on, well, what’s the benefit here that we're potentially paying more for. We're seeing obviously the clinicians becoming employees of hospitals and hospital systems. So, their independence and ability to kind of dictate what products they want to use are also declining. So, there is this trend that we do think is important, but I don’t want to give the suggestion that it's completely outside of doctors' and clinicians’ hands entirely.

Scott Nelson: Right. Yeah, no, no, I wholeheartedly agree with you, and anyone who thinks that physicians have no impact, I mean, it's foolish. In fact, in my opinion, they still have a lot if not the majority of the influence, but with that said, they just have less arrows in their quiver…

Jonas Funk: Yeah.

Scott Nelson: … to use when they're in some of these value analysis meetings and whatnot. But anything else about the survey that stands out before we kind of get into some of the key outcomes?

Jonas Funk: No, I think we've covered the main points of it.

Scott Nelson: Okay, so let's jump to sort of the four key questions that medtech companies need to answer in light of the data from the survey as well as just your research and sort of insight in dealing with this space.

Jonas Funk: Yeah, sure. So, I think there are four key questions that we have kind of identified that I think together help kind of illuminate the need for companies to kind of build from just thinking about excellent products to be thinking about what we call customer excellent in addition to product excellence. So, the four questions that kind of relate to customer excellence is, first and foremost, what problems can we solve or at least help solve for our customers? So, obviously, every company has a portfolio of products and there's a range of different things that those products do, but often it can get very muddled, particularly from the point of view of a hospital administrator that's looking at a large number of potential partners and that's trying to find a smaller number of partners to work with more closely. 

It's really helpful if those partners can be very clear about what problems they're solving. Is it they're going to help reduce hospital-acquired infections or are they going to help lower readmission rates for certain types of patients like heart failure patients? Are they going to help improve productivity or efficiency in a certain department like the OR, or the Cath lab? Are they going to help reduce medication errors? There's a whole host of problems that hospitals have, and having good clarity about what problems a medtech company is really all about solving is a pretty critical first question to answer. It's not to suggest that there aren't multiple problems that a single company can be trying to solve, but I think that's a good starting point, what are the key problems that you're trying to solve for your customers?

Scott Nelson: Got it. And before you move on to the second one, I love the fact that you touched on this and that seems fairly obvious, figure out what problems customers are motivated to solve that are relevant to your exact offerings, but so many medtech companies lose sight of the fact that they need to be more clear and communicate better in regard to how their products solve those problems. So. I'm glad you touched on that.

Jonas Funk: The second one is, given that problem, what’s the optimal solution for that problem in terms of not just the products but also some of the services that could be part of that solution? Sometimes the optimal solution can involve kind of capabilities that might be outside of a medtech sweet spot. That doesn’t mean that that can't be part of the solution. Whether it's the acquisition or partnership, medtechs, we think, are going to need to be more proactive in essentially reaching out, finding both product and service extensions to make their solution really come to light. A lot of that's going to involve healthcare IT platforms and partnerships as so much is moving towards a need for better metrics and monitoring of outcomes. So, just having a good product isn't good enough if you can't help monitor and measure its outcomes. So, a closer review of what actually is the solution and what appropriate products and services should be part of that is the second question.

Scott Nelson: Got it. A recent example of that, tell me if you agree with this would be Medtronic’s recent acquisition of, is it Cardiocom, I think was the company? Would that be an example of this?

Jonas Funk: Yeah, that's a perfect example.

Scott Nelson: Okay.

Jonas Funk: I think Medtronic is probably taking the lead in communicating at least the broader goal of becoming more of a solution player, of expanding into more healthcare services, recognizing how the landscape is shifting. Cardiocom, which is a company that Medtronic just acquired, I think it was just a week ago, maybe two weeks ago, to help with the remote monitoring of patients for heart failure and ultimately for other chronic disease states as well, that kind of bridges the gap between acute settings and non-acute settings, and ultimately Medtronic, I think rightfully, is positioning itself to be a broader kind of solution player that isn't just dealing with the problems within the hospital but also is helping take it outside of the hospital, which I would expect to be attractive to ACOs and more integrated systems as they take on more accountability and care a lot more about things like readmissions for heart failure patients.

Scott Nelson: Got it.

Jonas Funk: So, yeah, that's a great example. Others like the Stryker acquisition of Ascent, a reprocessing company that takes devices and reprocesses them to give hospitals an option for a lower-cost kind of solution for its instrumentation in the OR. So, giving not just the existing products but a reprocessing service on top of that is another good example.

Scott Nelson: Got it.

Jonas Funk: BD made an acquisition of a company called Cato. That's a software company, you know, kind of outside of BD’s kind of the traditional core, but again kind of expanding their reach and broadening their solution to help hospitals reduce the risk of medication errors. So, just a couple of examples of companies that are taking some steps outside of their comfort zones, but expanding their offerings to be a bit broader solution that ultimately I think will be the way that all companies will need to be successful.

Scott Nelson: Got it. Those are great examples, and in fact, I don't know when BD acquired Cato. I'm not sure when that was, but that's another interesting example. So good, let's shift to that third kind of key question.

Jonas Funk: Yeah. So, we talked about knowing what your problem to solve is, that's the first one. The second one is around understanding what the optimal solution should be. The third question is, well, how much value can you actually bring to your customers with that solution, and how do you quantify it? Because, increasingly, the threshold for success or the need that the hospitals are asking for is just a much higher threshold for how does this solution actually helps me?  

So, just saying that your products or solution is going to help reduce, say, hospital-acquired infections, isn't good enough. You have to actually be able to show very specific, well, these are the types of infections that the solution will address. This is the frequency by which those infections will be reduced. This is the cost of those infections. Being very clear about what that value is that the medtech company is bringing to the customers is become much more critical as hospital customers and administrators are just putting looking at things in a finer light and needing to have a strong economic argument to justify any sort of significant change, and certainly to justify any sort of solution that's priced at a premium.

Scott Nelson: Got it.

Jonas Funk: We're talking a lot about economic value, and I'm emphasizing that over kind of the clinical value because I think medtech companies have historically placed a lot of emphasis on the clinical value and communicating that to the clinicians. I'm not suggesting that that clinical value is still important. I'm just kind of making the point that increases the need to communicate how much value in economic terms is becoming table stakes as well even though currently the medtech companies aren't doing a great job of that.

Scott Nelson: Yeah. Great. That makes sense. So, let's move on to that fourth major question.

Jonas Funk: Yeah, well, that's just an extension of the last question about the value proposition, and what’s the best way to communicate and deliver on that value proposition? So, what types of documentation or evidence and tools can help the medtech company focus and clarify the value proposition to the right stakeholders?

Jonas Funk: So, in many instances, the stakeholders that might benefit from a solution might be in multiple different departments and in very different needs and kind of perspectives. So, for example, helping reduce medication errors, we’ll say infection control, that can help administrators reduce the cost associated with those HAIs. It can help the risk management people within the administration, and obviously, it can help the clinicians and other nurses and doctors as well. So, a bunch of different stakeholders will benefit, but actually being able to put together a clear set of documentation and tools that kind of appropriately focus the right message to each of those stakeholder groups in their terms is the last thing that I think medtech should be thinking about in terms of, how do they effectively take that solution, define the value proposition, and communicate it to the right folks?

Scott Nelson: Got it, yeah. Like you just said earlier that fourth key question is basically we've got our sales and marketing arm, how do we take what we've learned and what we feel like hospitals need and the problems that we can address, how do we actually communicate that effectively?

Jonas Funk: Yeah, and one of the things that, going back to your earlier question about kind of the challenges that executives are facing, I mean, there are existing large, established sales forces out there that have been doing things well for a long time, and it's hard to suddenly shake that up and say, well, now we need to be talking to these stakeholders and be making these different types of arguments and messaging. That's just a bit of a seat change that takes some time for companies to transition through.

Scott Nelson: While on that topic, I presume you see that as a slow transition, but maybe can you speak to how you see that transition actually taking place? Is this taking an existing sales force, for example, just focusing on sales for lack of time versus marketing, and coaching them up to be better communicators or maybe sell to different stakeholders, or do you see that transitioning happening where sales forces are simply reduced or replaced by folks that are maybe more proficient in communicating economic value, for example? Can you speak to that topic?

Jonas Funk: Yeah, I mean, I think it's a little bit of all of the above and there isn't kind of a single right solution. But I think arming the sales organization with the right tools, and a lot of that is the economic tools, is certainly part of that. Whether it's kind of making changes to kind of the existing people or retooling and rearming those same people I think is kind of dependent on individual companies and obviously individual people.

Scott Nelson: Yeah, right.

Jonas Funk: But I do think there is an organizational element to this as well where instead of having an army of current traditional sales reps that are relatively product-focused, going at the same institution, and frankly often causing some frustration among the administrators and causing kind of confusing messages for clinicians who are getting a lot of different reps talking to them, I think what we're seeing at least from our hospital survey is a wish for a more coordinated approach, fewer people, fewer touchpoints, but much higher value delivered when those coordinated kinds of visits are made. 

So, you might have a single point of contact for an entire IDN or at least for key stakeholders at large systems that bring in specialists in health economics, or product specialists or clinical specialists as needed to help address specific questions with a deeper, more valuable answer versus a generalist that is forced to try to touch a lot of different stakeholders asking for different things. So, I do think there's kind of some structural change in how the sales organizations are deployed and some corresponding rearmament of the tools and messaging that needs to go with that.

Scott Nelson: Yeah, I like that description, a kind of retooling is probably what we're going to be seeing over the next several years.

Jonas Funk: Right.

Scott Nelson:  So, using those four key questions as sort of the foundation, let's talk about kind of the four-step process that you feel medtech companies need to embrace in order to get to that level of customer excellence.

Jonas Funk: Sure. So, the first one is what we call developing a deep understanding of customer needs, and that's obviously related to understanding what problems a medtech is intending to solve for its customers. So, you've got to understand your customers’ needs, and that's just basic marketing 101. The problem though is that a lot of medtechs have historically spent less time understanding customers’ needs as opposed to trying to figure out ways to incrementally improve products or tweak the products to add additional features and functions often independent of understanding how those might fit customers’ needs. When we talk about customer needs, definitely don’t want to give the impression that hospitals are monolithic, and all have the same needs. In fact, there's such huge variation that one of the things that we find a lot of our medtech clients asking for these days is understanding hospital segments and how is the right way to think about the universe of hospitals out there so that you're not giving the same solution or the same messaging to a small-world hospital as you are to a Mayo Clinic. They just have a very different set of behavioral characteristics, and the need to understand how those behavioral characteristics vary and what the appropriate segments to go after we think is an important element of understanding customer needs as you're developing solutions to address those problem areas.

Scott Nelson: Got it. Okay. Okay.

Jonas Funk: The second one would be around that optimal solution for the problem at hand and we what call here as an integrated portfolio that almost necessarily includes services that help make those products come to life more. Again, you don’t have to have all of the components yourself as a medtech. You might partner with a healthcare IT company or partner with a service-focused company to help provide that, but you're quarterbacking that delivery, pulling it together, and making it into an integrated solution that can actually address that need to reduce hospital-acquired infections, reduce readmission rates or whatever the problem is that you're targeting.

Scott Nelson: Okay. Do you have an example maybe what that looks like or will look like if it's not being offered right now for medtechs?

Jonas Funk: Well, that's where I think the Cardiocoms and the Stryker Ascents or the BD Cato software acquisitions come into play. I mean, I think you're seeing companies that are starting to branch out their portfolios in kind of new ways. We, LEK, are also seeing our medtech clients coming to us and saying, gee, what about services? What can we do in services? Are there things that we can do in procurement or inventory management or in clinical decision support systems and analytics…

Scott Nelson: Okay.

Jonas Funk: …that go beyond the kind of just the products? And what’s the need out there? What are companies that are doing these things today? How can we partner with them or potentially even acquire to offer that broader functionality?”

Scott Nelson: Got it. That's why you mentioned maybe a big growth engine looking into the future is going to be health IT, because so many of these, whether it's an analytics platform or a clinical decision-making platform or some sort of economical platform, it's going to be largely driven by technology or more specifically by software. So, that's why I can see that you mentioned health IT is going to be big looking into the future.

Jonas Funk: Yeah, or at least data and data analytics…

Scott Nelson: Sure.

Jonas Funk: …which everyone knows that that’s important, and that's obviously where most of the hospital spending growth is. A lot of spending has been done on developing IT systems. Now a lot of the money is being shifted toward how do they integrate those systems and do analytics with the data that they have so that they can actually use the data, not just collect the data. So, that spend on healthcare IT will continue in the future for sure, but I think that the challenge for the medtechs will be to leverage the data that is useful and help the hospitals convert that into something that can actually result in improved efficiency or outcomes within the departments or hospital functional areas that those medtech companies are focusing on.

Scott Nelson: Okay. Yeah. That makes sense. Great. Is there anything else to add under this bullet point of kind of the integrated portfolio and value-added services umbrella?

Jonas Funk: No, I think the next point probably brings it to life a bit more, which is around making very sure that, that value that, that solution that you are offering is clearly articulated. It might sound obvious and easy to do, but it's shocking how rarely we see medtech companies do a good job of this. I mean, in most other industries, whenever you make a claim about your value proposition, you often have to back it up and show it, but yeah, I think in healthcare it's tricky, and medtech companies historically have not had the need to do so because clinicians have been very happy to adopt the latest and greatest technology without really putting the pressure on to say, “Well, how exactly is this helping in terms of reducing our costs or improving outcomes in nonclinical ways?” So, the bar I think is growing for medtech companies to do a better job of articulating the value proposition in economic terms.

A good example here, we've done some work helping a client that had a prefilled syringe solution that would help hospitals in a lot of ways. So, everyone knows that, well, prefilled syringe solutions are good at helping reduce medication errors, they reduce some of the labor that's involved in preparing the syringes, they can help reduce some types of waste, and there are some other kinds of smaller benefits that are out there. But the problem was the benefits accrue to different types of stakeholders, and a lot of these benefits are just very difficult to quantify.

That made it difficult for our client to be able to actually get the pharmacy directors to approve the purchasing of prefilled syringes because the pharmacy directors really just cared about their budget and didn't care as much about some of the things that were happening outside of the pharmacy. It required a robust effort to walk through the process, identify all the points in the workflow where medication errors can occur. What the rate of medication errors is? What type of errors could be addressed by prefilled syringes? How much direct cost those errors tend to incur? How much the indirect costs can incur, and turning this into a clear economic model that actually shows how all of those different benefits that, in this case, prefilled syringes, could provide to the hospital that went well beyond just a pharmacy director. That's the type exercise that I think medtechs are going to have to do much more consistently to show in economic terms at the end of the day why a hospital should adopt their solutions versus either staying with the status quo or going with someone else’s.

Scott Nelson: Got it. Okay. That's good stuff. That's good stuff. Let's move on to that fourth step in this process.

Jonas Funk: Yeah. Well, the fourth step is then just taking that kind of clearly articulated value proposition and turning it into the appropriate set of tools and documentation and knowing which people to share that with. So, for example, even knowing at an individual hospital, who are the right influencers? Is it part of an IDN? Is the decision being made at an even more centralized location? What is the right target to go after is often not as clear as it used to be, right?  If the call point in the past was the orthopedic surgeon that was in the OR, but now there's more centralized decision-making, and obviously the IDNs are consolidating and buying up other hospitals. 

So, it's becoming a little bit harder to know even, how do you define an account? Who are the decision-makers within that account? And then once you can answer those questions, then it's a matter of, well, who are the right people within the medtech’s organization that should be calling on those decision-makers? And oftentimes we're talking about pretty senior centralized decision-makers that are going to need to see very compelling arguments backed up by economic models and clear value proposition articulation that frankly is not really being delivered today in many companies.

Scott Nelson: Right.

Jonas Funk: So, you don’t want to develop a value proposition but leave it kind of on the table or trying to share it with people that aren't going to be able to do anything about it.

Scott Nelson: Right. Yeah, that is sort of the clear and last step or end step in the process, is taking that data, that value, that message, and actually delivering it at the right time to the right people. I think if I remember correctly, leading up to this interview you sent me maybe a different report, and I remember reading a comment from…or maybe it was a couple of comments from hospital administrators to that point of they’ve got like a lot of contacts at medtech companies but they were rather frustrated that they would actually prefer one contact versus many, for example.

Jonas Funk: That's right.

Scott Nelson: Yeah.

Jonas Funk: That goes back to the kind of the single point of contact with a set of specialists versus kind of a generalist army that goes after primarily clinicians.

Scott Nelson: Got it. And that's obviously in contrast to a lot of how device companies are organized and oftentimes divided into sort of business units by a therapeutic area that may be looking into the future. It’s not the best way or maybe the most effective way from an organization standpoint.

So, let's just review, because there’s a lot of really good stuff in those four steps. Let's just review those real quick. So, the first step would be to have a deep understanding of what your customers, in these hospitals, need, not just physicians but all key stakeholders basically, what they really truly need. Be able to offer an integrated portfolio of products and in some cases complimentary services. Third, being able to clearly articulate that value proposition, and then lastly, to sort of not necessarily to sum it up, but the last step in the process, would be making sure that you present that data and that offering to the right folks, to the right audience and the right team. Is that a decent summary?

Jonas Funk: I think that's right. I think for someone that might be outside of the medtech industry, that might sound just very, very obvious. Perhaps the people within the medtech industry too, but again, if you apply a reasonable perspective on kind of how medtech companies have been doing this for the last 30 years, I think it's fair to say that these four steps are often not well-executed.

Scott Nelson: Yeah.

Jonas Funk: So, understanding customer needs has not been kind of first and foremost. Having integrated portfolios that actually holistically address a problem in a very customer-centric solution-oriented manner, not often well-executed. Understanding and articulating the economic value proposition, very unusual and very rare for medtech companies to do that on a consistent basis. And then finally on delivering the message to the right audience. Given the changes in decision-making, it's not surprising that it's hard to flip a switch and change all the relationships that have been built up over the last few decades among the sales organizations and suddenly say, okay, now go talk to different people with a different set of needs.

Scott Nelson: Right.

Jonas Funk: It's not surprising that it's kind of evolved the way it has, but going back to your initial question, what keeps the executives up at night in the medtech industry? I think it’s; how do they evolve from the past state to the new world and the new world and the future where these four steps are just going to have to be like clockwork.

Scott Nelson: Right. As simple as those four steps sound, there are so many moving parts that when you actually take each step and sort of silo it, if you will, because of all the moving parts and the constant change, it actually gets somewhat overwhelming when you kind of begin to think about…

Jonas Funk: Yeah.

Scott Nelson: …a particular product franchise, for example. And so, you know, I'm not sure if you would agree with this, Jonas, but maybe a good exercise would be if you're a director over a certain product franchise within a medtech company, maybe sitting down and looking at each of your product buckets and going through this four-step process would be a great idea. Do I really truly understand the needs that this product is supposedly meeting? What other value-added services could we potentially offer alongside this product? Are we clearly articulating the value of this product? And then lastly, are we presenting to the wrong audience? Do we have the right message, etc.? So yeah, I like what you said though: As simple as maybe those sound, because there are so many moving parts, it’s a really good thing to kind of go back to those basics in a sense.

Jonas Funk: Yeah. Yeah.

Scott Nelson: Great. So, in light of that, do you offer this survey? I presume you're willing to offer it to anyone who requests it, correct?

Jonas Funk: Yeah. The hospital survey that we do every year is something that we do to share with our clients and prospective clients. So yeah, happy to share that with people that are interested.

Scott Nelson: Yeah, and I presume…I guess let me ask you that before we move on to the next question. What is the best way for folks listening to this that want to either reach out to you directly or maybe want a copy of this survey? What would be the best way to do that?

Jonas Funk: I think probably just go to the LEK…

Scott Nelson: Hey, Jonas? Jonas?

Jonas Funk: Yeah, Scott, I was just saying, the best way to reach me or LEK would be to just go into the LEK website.

Scott Nelson: Okay.

Jonas Funk: So that's lek.com, and within that, it's not hard to navigate to our medtech practice, and from there a lot of the information is in fact available in our executive insight documents, and my contact information is in there as well.

Scott Nelson: Okay. So lek.com. I’ll of course link up to that in the show notes for this interview. So, in light of that four-step process, and then even before that, the four key questions that we covered, in your opinion, what do you think medtech companies need to implement like right now or immediately versus maybe something that they need at the very least have on their radar looking three, four, five years down the road?

Jonas Funk: Yeah. I mean, I think the thing that I would recommend is something that I get a lot of calls about, which is making sure that the current products that medtech companies have to do in fact create economic value for their customers because I think the bar for clinical value is set. That's just table stakes. If you can do better, that's great, but the “good enough” mentality is becoming pretty strong, and so in order to gain traction, there is a need to show the administrators that there's an economic benefit as well. So, the discipline of putting into effect in the organizations a more clear articulation of that value proposition I think is very doable, because I think what will happen is in some cases, you know, people will look up in the mirror and see, “You know what? We're actually not creating a lot of value with this product or this set of products.” 

That should raise a red flag to either kind of move to others or find ways to make the existing products actually do more. The reason why this is particularly important is because in the next several years we expect that hospitals are going to increasingly look for some kind of risk-sharing and gain-sharing arrangements with their suppliers, and if you're unable to clearly understand the economic value that you're bringing to your customers, you will not be in a position to offer any sort of risk-sharing or gain-sharing arrangement. So, this is a kind of prerequisite for those types of programs which we think in the future will become much more likely.

Scott Nelson: I think that's really important. We don’t have a lot of time, but can you briefly touch on that concept or that idea of risk-sharing and gain-sharing?

Jonas Funk: Sure. I mean, if you ask the hospitals what they want to see from medtech companies in the future, the thing that pops to the top of the list in terms of changes from today is they want to see more of that, more risk-sharing and having their suppliers basically put their money where their mouths are.

Scott Nelson: Yeah.

Jonas Funk: And say, “Hey, we're going to adopt these products, but we want you to be our partner and share in the risks and rewards associated with that.” So, there's a strong latent need from hospitals for those types of arrangements, but frankly, hospitals don't know much about what that involves other than wanting to shift some of the risks away from themselves. So, the current state of risk-sharing programs is very nascent, and you don’t really have any good examples within the device space of true risk-sharing arrangements that I've seen. But that’s not because there isn't a demand for it, I think it's more because the suppliers haven't been able to figure out a way to offer it that actually works and that has available metrics to monitor to enable kind of a two-way win. But before they can get there, again, they need to understand how much value they're creating in the first place…

Scott Nelson: Right.

Jonas Funk: …to be able to say how much they can share and how much risk they're willing internally to take on.

Scott Nelson: Yeah, nearly impossible to come up with some sort of risk-sharing agreement that would work without clearly understanding the economic value that you actually bring to the table.

Jonas Funk: That's right.

Scott Nelson: Yeah. Great stuff. Yeah. Do you still have a few minutes? Is this okay?

Jonas Funk: Yeah.

Scott Nelson: Okay.

Jonas Funk: Yeah.

Scott Nelson: Real quick. I mentioned this at the beginning of the interview, but you opened or cofounded L.E.K.’s Tokyo office, correct?

Okay, so we're back. Slight technical difficulty there, but the last question I had for you, Jonas, is I believe you opened or co-founded the Tokyo office for L.E.K. Can you speak about that? Because you're kind of a Midwest guy. You at least went to school in the Midwest. So, how did you end up over in Japan?

Jonas Funk: It was at the time a neat opportunity to spend a bit of time in Japan and the six-month project turned into a six-year stint. So, it wasn’t planned but an interesting path to take, nonetheless.

Scott Nelson: I've got to think though that your experience over in Japan is probably a huge value add that you bring to the table in terms of helping medtechs focus on kind of their strategies [53:44 inaudible].

Jonas Funk: I mean, Japan was and still is a critical part of a lot of device companies’ geographies. It's been a large profitable market even though it might not be growing as fast as some of the other Asian countries. But yeah, it has a lot of unique characteristics and challenges to overcome to kind of tap into that opportunity. So, that was something I helped a lot of our clients deal with.

Scott Nelson: Got it. Great stuff, and I can't thank you enough for coming out on the program and taking some time out of your schedule to help us learn a little bit more about the insights that you gleaned from this most recent L.E.K. hospital survey and what the impact is for medtech companies. So, thanks again for your willingness to do this.

Jonas Funk: No, my pleasure, Scott. Appreciate it.

Scott Nelson: For those listening who have hung on this long. If you're interested in listening to other Medsider interviews, just go to medsider.com and click on the radio button, and that will provide you with a couple of different links to download all of the audio files, whether you listen to them in iTunes or Stitcher Radio or whatever app you prefer. So, check it out when you get a chance.

Check Out the Podcast →

Sponsors

  • FastWave Medical: Named MD+DI's Company of the Year, FastWave is one of the hottest medtech startups in the cardiovascular space. See how you can invest here.

  • Fundraising Cohort: Planning to raise capital for your startup? This live, 4-week workshop, led by Scott Nelson, is designed to help founders and CEOs tell a sharper story, get investor meetings that matter, and close real capital. Join the waitlist here.

Don’t Forget

Interested in advertising with us?
Get in Touch →

Want to learn from more startup CEOs?
Check Out the Archive →

Forwarded this email?
Join for Free →

Who's Scott Nelson again?
See His Bio →

Transcript

0:00:00 [upbeat music] Welcome to MedSider, where you can learn from experienced medical device and med tech experts through uncut and unedited interviews.

0:00:19 Now, here's your host, Scott Nelson.

0:00:30 According to a recent L.E.K survey of hospital executives, fifty-six percent of the respondents have taken steps to reduce medical device sales rep access to their facilities.

0:00:41 In fact, the CEO of an Illinois hospital stated, "We're constantly trying to limit the sales reps. We want to see what they're selling before they get ahold of a doctor who brings it in without our knowledge."

0:00:51 At least one s- one answer is obvious, right? Hospitals are clearly not looking for advice from medical device sales reps. So what solutions are they looking for?

0:01:00 Here's what a director of purchasing in a Minnesota hospital wants. We would really like clinical outcomes data.

0:01:06 For example, we want to know if a knee replacement that costs two times as much as a competitor's knee is actually going to last double the time as the competitor's model.

0:01:14 In other words, hospitals want to understand the cost benefit analysis for the medical devices they purchase. That's one idea med tech companies need to embrace. But what are the other three?

0:01:23 In this interview with Jonas Funk, managing director at L.E.K.'s Chicago office, we learn about the four-step process that medical device companies should consider in light of the current healthcare environment.

0:01:33 Here are a few of the points that we're gonna cover in this interview with Jonas. What are the most pressing challenges that med tech executives are facing right now?

0:01:40 We're gonna learn and get an overview of L.E.K.'s most recent strategic hospitals priority study, how it was conducted, who was involved, et cetera.

0:01:49 In the pursuit of customer e- excellence, what are the four key questions that med tech companies need to answer right now? Are hospital administrators the new KOLs?

0:02:01 And what is the one concept that medical device companies need to implement right now?

0:02:06 Of course, there's a lot of other subjects that we're gonna cover in this interview, but before we dig in, listen to these brief two messages.

0:02:12 First, to get free email updates when another MedSider episode goes live, simply go to medsider.com/free. We don't send emails often, but when we do, they're full of valuable content. No spam ever.

0:02:26 Just go to medsider.com/free to sign up. Second, MedSider is on iTunes. Just go to medsider.com/itunes, and you can subscribe to the podcast for free.

0:02:39 That way, all the new episodes will automatically download to your iTunes account. It's super easy. Also, if you like the podcast, don't forget to rate it. That really helps us out. Okay.

0:02:49 For you ambitious doers, here's your program. Hello, everyone. It's Scott Nelson, and welcome to another edition of MedSider. And for those of you who are new to the program, uh, this is a show where I,

0:03:02 uh, interview experienced, uh, med tech and medical device thought leaders in an effort to, uh, learn as much as possible and then hopefully implement, uh, one or two, uh, big takeaways.

0:03:13 And, uh, today's guest on the program is Jonas Funk, who is a managing director and partner in L.E.K. Consulting's Chicago office. He has more than fifteen years of experience in L.E.K.

0:03:23 and has directed hundreds of consulting engagements, uh, primarily focused on growth strategy and, uh, mergers and acquisition support within the med tech and life sciences verticals.

0:03:34 Uh, Jonas also co-founded the Tokyo office and has assisted dozens of clients in developing their Asian strategy. So without further ado, uh, welcome to the program, Jonas. Great to be here, Scott. Thanks. Okay.

0:03:48 So Jonas, let's start here. Um, you, you have the, uh, the opportunity to consult with, uh, h- discuss with, and, and probably in m- in a lot of cases present to, uh, a lot of med tech executives and decision makers.

0:04:01 So in your opinion, what do you think are, um, are the one or two most pressi- pressing challenges that, uh, that those folks are facing right now? Yeah.

0:04:12 Um, I, I mean, I think the biggest challenges that they face kind of relate to, you know, how to navigate some pretty substantial changes that are occurring in the healthcare industry, and, you know, particularly with respect to transforming their organizations to be successful, um, to, to be successful med techs going forward.

0:04:33 And, you know, fundamentally what we're seeing is a shift from, you know, the old fee for service world to a new world, uh, where outcomes are gonna be much more important and costs are, are much more important.

0:04:46 And the old model that med techs were very successful with, um, is, is not gonna be as successful in the future.

0:04:52 So the kind of, you know, making great products and convincing clinicians to use them, uh, worked well for a long time, but, but given some of the macro changes that we're seeing, uh, that model is, is very much, um, changing.

0:05:07 And the challenges that, that a lot of our clients are, are facing is how to, uh, essentially, you know, um, respond to those, those, those changes given that a lot of the historical focus and capabilities have been in, you know, um, kind of areas that, that might not be as well aligned with the success in, in the future.

0:05:28 So, um, that's probably the, the high level [chuckles] um, summary of, of what's keeping them up at night. Got it.

0:05:36 And we'll, we'll probably, uh, we'll, we'll definitely get a chance to dig into, to, um, some more, some more details for sure. Um, but you've been with L.E.K. now, um, for, for quite a few years.

0:05:46 Does it seem like-- Before I ask you a little bit about your background at L.E.K.

0:05:50 in general, does it seem like, uh, now, uh, now is just a more crazy time, uh, than, than it ever has been within sort of the healthcare space?

0:06:00 Yeah, I think that's right, and I think some of the- You know, uh, changes are, are actually happening faster than the healthcare industry has been used to. Mm-hmm.

0:06:08 And so it is, um, kind of required for executives to, to be able to respond, you know, faster than, than I think was required in, in the past. So yeah, I think that's right.

0:06:21 A lot of, a lot of changes, both from a, a reimbursement, a regulatory perspective are, are, are out there, but at the end of the day, it's, it's hitting the manufacturers in, in very specific and important ways that, um, I think they're

0:06:36 c-collectively trying to get their heads around and, and respond to. Got it. Okay. So we're, we're gonna, um, we're definitely gonna dive into, um, the release of your 2013 hospital priorities study.

0:06:49 Uh, but before I ask you about that study and then some of the, um, some of the ramifications or, or, um, outcomes that, that you uncovered in, in this, in this most recent study, um, give us a little...

0:06:59 Give me, uh, give me and the audience a little bit of an overview about your background, uh, and then also, uh, LEK in general. Sure. So, um, I think you summarized my background pretty well.

0:07:11 I've been doing this for about 15 years. I spend pretty much all of my time in what we call the med tech space, uh, and, and helping our med tech clients grow and, and develop strategies to grow.

0:07:24 Um, LEK is a global management consulting firm, about 1,000 people wor-worldwide, uh, offices in 20-plus countries.

0:07:33 Um, and our hospital survey that you, that you alluded to, um, is our fourth, uh, annual hospital survey.

0:07:41 So we've done this four years in a row, and the goal of the, the study is to, to, to essentially get a good sense of, of what hospitals are thinking in terms of their purchasing, uh, patterns and their, and their needs with respect to med tech companies.

0:07:58 Uh, and so we've been, uh, surveying and monitoring those, those needs and perspectives for the last several years to get a, you know, kind of ongoing sense of what their, what their wishes are [chuckles] of their suppliers, as well as to get a, a better sense of how some of the, the industry changes are manifesting, you know, in, in kind of the hospital's minds.

0:08:18 Got it. Okay. And I wanna ask you a little bit more about, uh, you know, how the, how this particular study, uh, is conducted each year.

0:08:24 But, um, in regards to your background, um, I, if we have time, I definitely wanna, I w- I definitely want to, uh, ask you about your time in Asia 'cause that's, um, uh, that's definitely interesting.

0:08:34 So hopefully we'll have time for that. But, uh, one question in regards to LEK. Um, your, L-LEK's consulting sort of services, you span a lot of different verticals. It's not just med tech and life sciences, correct?

0:08:47 That's right. Um, but in the US, almost 50% of what we do is, is healthcare- Okay... related. Okay. And within healthcare, we have sectors that are focused on the payers or the providers, um, biopharmaceutical companies.

0:09:02 And then for me personally, I'm focused in our med tech practice- Okay... uh, w-working with a lot of the big medical device and, and diagnostic players. Got it. Okay.

0:09:10 Um, so let's, let's, uh, let's transition to the act- the, the 2013 hospital study. Can you, uh, uh, provide us with a little bit more, uh, detail in regards to, you know, how it's typically conducted, um, you know, who,

0:09:23 who's involved, uh, a-and maybe more specifically, um, where are you getting the responses from, uh, in terms of, uh, the, the role, you know, the, the, the role at the hospital that, you know, a particular person would play?

0:09:35 Uh, and then, um, and then, you know, let's talk about some of the, uh, we'll t- and then we'll segue sort of into the, some of the key outcomes of the study. Yeah. Of course. So it's, um,

0:09:45 for the last four years, we've done it, and it's been focused on hospital administrators, uh, versus clinicians.

0:09:51 So, um, very intentionally, we've been focusing on the administrators and, uh, about 200 respondents to our, to our survey across a representative mix of hospitals, big and small, academic, non-academic, um, urban, rural, and, and so on and so forth.

0:10:09 Um, and of the respondents, about 100 of those are C-suite, so CEOs, CFOs, COOs, uh, versus the other 50% that are kind of other administrators that are involved in the, um, purchase decision-making process.

0:10:26 So, uh, VPs of procurement, materials managers, um, and, and, and people basically in the purchasing functions at hospitals. Got it. Okay.

0:10:37 Um, and you mentioned just, that's in- an interesting sort of side note, but you, you touched on it just real briefly.

0:10:43 These are responses not just from, um, you know, larger, you know, 500-plus bed hospitals in major metro, metropolitan cities. Mm-hmm.

0:10:50 Uh, you're also getting responses from more, you know, from, from the outlying community hospitals as well? That's right. Got it. That's right. It's, it's intentionally a representative mix of, of the overall market.

0:11:01 Got it. And this, and your hospital priority study, has it always focused on administrators, uh, versus, uh, versus or in contrast to clinicians?

0:11:09 It, it has, um, although I think over the last year or two, we're particularly, um, uh, I'd, I'd say glad [chuckles] that it's been focused- Yeah...

0:11:21 on administrators because, um, several years ago, we, we saw the, the beginning of a trend for greater influence, uh, among the administrators in, in purchase decision-making.

0:11:31 So we thought it would be a good group to, to start surveying.

0:11:34 And indeed, over the last several years, we're seeing a very pronounced trend for a greater, greater involvement and influence of those, uh, decision make-- of the administrators in the decision-making process and their respective needs for kind of more economic considerations, not just the clinical considerations that, you know, we've typically been used to, um, among the clinician stakeholder groups that have been the primary call point targets for med tech companies for a long time.

0:12:03 Yeah. And I, and, and I'm, that's why I'm, I'm pretty anxious to get into, into the, uh, the outcomes of this, of this study and what it means for, for med tech and medical device companies.

0:12:11 Um, but I love the fact that it's, it's administrator focused 'cause, you know, so many, so many times the word, the word KOL or key opinion leader, you know- Right...

0:12:19 within the med tech space is often thought of as the clinician or the physician. Uh, but [chuckles] but more so now than ever, you know, it's, it's gonna be probably, you know, um-

0:12:29 You know, administrators within large health systems and, um, or not just health systems, but administrators in the hos- in, you know, in large hospitals as well that, that are- Yeah...

0:12:37 you know, gonna be considered [laughs] KOLs, uh, which is, you know, kind of an interesting concept, um, if you're, if you've been- I-... sort of entrenched in med tech for a while. Yeah.

0:12:46 I think that's, that's generally right. I don't wanna kind of overstate it.

0:12:49 I, the clinicians in, in particular, you know, leading clinicians and, and key opinion leaders and department heads certainly have, uh, you know, a point of view that they will share, uh, that can be, you know, very influential in specific departments or for specific products.

0:13:06 But the, the general trend that we're seeing is a kind of gradual migration from kind of the, you know, the clinician chooses what product he or she uses to, at the minimum, you know, kind of a, a conversation or a, you know, value analysis committee decision that involves administrators where there's much more scrutiny on, well, what's the benefit here that we're po- potentially paying more for?

0:13:29 Um, and we're seeing, you know, obviously the clinicians becoming employees of, of hospitals and hospital systems, so their kind of independence and kind of ability to, to kind of, um, dictate what products they, they wanna use is, is also kind of, uh, declining.

0:13:47 So there is this, this trend that we do think is important, but I don't wanna give the suggestion that it's completely, you know, uh, outside of, of, of doctor and clinicians- Right... um, hands entirely. Yeah.

0:13:59 No, no, I, I wholeheartedly agree with you. And anyone who thinks that, uh, you know, that physicians have no impact, I mean, it's, it's foolish.

0:14:04 In fact, they still have, in my opinion, they still have a lot, if not the majority of, of the influence.

0:14:10 But with that said, you know, if you, uh, you know, they just have less, uh, arrows in their quiver, you know, um- Yeah... to [laughs] uh, to sort of, um, use, you know, when they're, um,

0:14:22 um, when they're, you know, in some of these value analysis sort of meetings, um, and whatnot. But, uh- Yeah...

0:14:28 um, any- anything else about the survey that stands out before we kind of get into to, to some of the, the key outcomes? No, I think we've, we've covered the, the main points of it. Okay.

0:14:37 So let's, let's jump to, um, uh, sort of the, the, the four que- the, the four... I said the que. The four key questions, I should say, um- [laughs]...

0:14:48 uh, that med tech companies, uh, need to answer in light of, um, you know, the data from the s- the, the survey as well as just your, you know, your, your research and, and, and, and, and, um, sort of insight, uh, in dealing with, uh, in dealing with the space.

0:15:03 Yeah. Sure. So there's... I think there's, there's four key questions that, that we've kind of identified that I, I think together help, um, kind of

0:15:16 i- i- illuminate the, the need for companies to kind of go from just thinking about, you know, excellent products to be thinking about, you know, the, what we call customer excellence in addition to product excellence.

0:15:28 So the, the four questions that, uh, kind of relate to customer excellence is, is first and foremost, uh, you know, what problems can, can we solve or at least help solve, uh, for, for our customers? So, you know,

0:15:46 obviously, you know, every company has a portfolio of products, and, uh, there's a range of different things that those products do, but, but often it can get very muddled, uh, particularly from the point of view of a hospital administrator that, that, that's looking at a, a large number of potential partners and that's trying to, to find a smaller number of partners to work with more closely.

0:16:09 And, you know, it's really helpful if those, those partners can be very clear about what problems they're solving.

0:16:15 Is it they're gonna help reduce hospital acquired infections, or are they gonna help lower readmission rates for certain types of patients like heart failure patients?

0:16:26 Are they gonna help improve productivity or efficiency in a certain department like the OR or the cath lab? Um, are they gonna help reduce medication errors?

0:16:37 There's a whole host of problems that hospitals have, and having good clarity about what problems, you know, a med tech company is, is really all about solving is, is a pretty critical first question to answer.

0:16:51 And it's not to, not to suggest that there isn't multiple problems that a single company can, can, um, be trying to solve, but I think that's a good starting point.

0:17:01 What are the key problems that, you know, you're trying to solve for your customers? Got it.

0:17:06 And, and before you move on to the second one, I love the fact that, that you, you touched on this and that, uh, that, that seems fairly obvious.

0:17:12 You know, figure out what problems are, you know, customers are, are motivated to, you know, to, you know, to solve that are relevant to, you know, your exact offerings.

0:17:20 But, but so many med tech companies lose sight on the fact that they need to be more clear and communicate better in regards to how their products solve those problems. So I'm, I'm glad you, I'm glad you touched on that.

0:17:32 Mm-hmm.

0:17:32 The second, the second one is, you know, given that problem, what's the, what's the optimal solution for that problem in terms of not just the, the products, but also some of the, the services that could be part of that solution.

0:17:47 Um, and, you know, sometimes the, the optimal solution can involve kind of capabilities that might be outside of a, a med tech sweet spot, and that doesn't mean that that can't be part of the solution, whether it's via acquisition or partnership.

0:18:03 You know, med techs, we think, are gonna need to be more proactive in, uh, essentially reaching out, finding the, um, you know, both product and service kind of extensions to make their, um, their solution really come to light.

0:18:19 And, you know, a lot of that's gonna involve, um, healthcare IT platforms and, and partnerships, uh, as, as so much is, is kind of moving towards a need for, for better metrics and monitoring of outcomes.

0:18:33 Um, so just having a good product isn't, isn't good enough if you can't help monitor and, and, and measure its, its outcomes.

0:18:41 Um, and so, you know, a, a closer review of what actually is the solution and what appropriate, um, products and, and services should be part of that is, is the second question. Got it.

0:18:55 And an exam- a recent example of that would, uh, maybe, tell me if you agree with this, would be Medtronic's acqui- recent acquisition of, of, is it Cardiocom, I think it was the, was the company? Yeah.

0:19:04 Would that be an example of, of this? Yeah. That's a, that's a perfect example. Okay.

0:19:08 I think, yeah, Medtronic is, is probably taking the lead in communicating at least the, um, the broader goal of becoming more of a solution player. Uh-huh.

0:19:20 Of expanding into more healthcare services, uh, recognizing the, how the landscape is shifting.

0:19:27 And Cardiocom, you know, which is a, a company that, um, that Medtronic just acquired, I think it was just a week ago, maybe two weeks ago, um, to help with, uh, r-remote monitoring of, of patients for, for heart failure and, uh, ultimately for other chronic disease states as well.

0:19:44 That kind of bridges the gap between, you know, acute settings and, and non-acute settings.

0:19:49 And, and ultimately, Medtronic, I think rightfully, uh, is positioning itself to, to be a, a broader kind of solution player that isn't just dealing with the problems within the hospital, but also is, is helping kind of take it outside of the hospital, which I would expect to be, uh, attractive to, you know, ACOs and, and more integrated systems, you know, as they take on more accountability and, uh, and care a lot more about things like readmissions for, for heart failure patients.

0:20:18 Got it. So yeah, that's a great example.

0:20:21 You know, others, I like the, the Stryker acquisition of, of Ascent, you know, a, a reprocessing company, um, that, you know, takes devices and, and reprocesses them to give hospitals a, an option for a lower cost, uh, kind of solution for its instrumentation in, you know, in the OR.

0:20:42 So, you know, kind of giving not just the existing products, but a reprocessing service on top of that is, is another good example. Got it.

0:20:50 BD made a acquisition of a company called Cato, C-A-T-O, uh, that's a software company, you know, kind of outside of BD's, you know, kind of traditional core.

0:21:00 Um, but again, kind of expanding their, their reach and, and broadening their solution to help hospitals reduce the risk of medication errors.

0:21:09 So just a, a couple of examples of companies that are taking some, some steps kind of outside of their comfort zones, but expanding their, their offerings to, to be a bit broader solutions that ultimately, I think will be, you know, kind of, um, you know, the way that, that all companies will, will, will need to be successful.

0:21:29 Got it. No, those are, those are great examples. And in fact, I, I don't know when BD, BD, uh, acquired Cato. Um, that's...

0:21:36 I'm not sure when that was, but that's, that's another, that's another interesting, interesting, uh, example. Um, so, so good. Let, let's shift to that third, uh, that third, that third kind of key question. Yeah.

0:21:47 So, you know, we, we talked about the, you know, knowing what your problem to solve is. That's the first one. The second one is around understanding what the optimal solution should be.

0:21:56 And the third question is, well, how much value can you actually bring to your customers, you know, with that solution, and how do you quantify it?

0:22:04 Because increasingly, the threshold for, um, kind of success or, or the, the need that the hospitals are, are asking for is, is just a much higher threshold for, how does this solution actually help me?

0:22:18 So, you know, just saying that your products or, or solution is going to help reduce, say, hospital-acquired infections isn't good enough.

0:22:28 Uh, you have to actually be able to show very specifically, well, these are the types of infections that the solution will address.

0:22:36 This is the frequency by which those, those infections will, will, um, you know, be, be reduced. This is the cost of those infections.

0:22:44 You know, being very clear about what that, um, value is that the, um, med tech company is bringing to the customers is, is really becoming much more, uh, critical as hospital customers and administrators are just putting a, a, you know, looking at things in a, in a, in a finer light and needing to have a strong economic argument to justify any sort of, uh, significant change, uh, and certainly to justify any sort of solution that's, that's priced at a premium.

0:23:14 Got it.

0:23:15 And there's, there's, you know, we're talking a lot about economic value, uh, and I'm, uh, emphasizing that over kind of the clinical value because I think med tech companies have historically, uh, placed a lot of emphasis on the clinical value and communicating that to the clinicians.

0:23:30 I'm not suggesting that that clinical value is still important.

0:23:33 I'm just kind of making the point that increasingly the need to communicate how much value in economic terms is, is becoming, um, table stakes as well, even though currently the med tech companies aren't doing a great job of that.

0:23:48 Mm-hmm. Yep. Great. That makes, that makes, that makes sense. And so, um, on-- let's, let's move on to that, that, that fourth major question. Yeah.

0:23:59 Well, that's just an extension of the, of the, of the last question about the, the value proposition, and that's, you know, what's the best way to communicate and deliver on that value proposition?

0:24:10 So, you know, what types of documentation or evidence and, and tools can help the med tech company focus and clarify the value proposition to the right stakeholders? Right.

0:24:23 So in, in many instances, you know, the stakeholders might, uh, that bene- the, the stakeholders that might benefit from a solution might be in multiple different departments and have very different needs and, and, um, kind of perspectives.

0:24:37 So, you know, for example, um, you know, helping Helping reduce medication errors or infection, let's say infection control, you know, that can help, you know, uh, ad-administrators reduce costs associated with those, those, uh, HAIs.

0:24:53 Uh, it can help kind of the risk management people within, within the administration, and obviously it can help the clinicians and, um, a-a-and other, you know, nurses and doctors as well.

0:25:03 So a bunch of different stakeholders will benefit, but actually being able to put together kind of a clear set of documentation and tools that kind of appropriately focus the right message to each of those stakeholder groups in the, in their terms is, is the last thing that I, I think, um, med tech should be thinking about in terms of how do they effectively take that solution, communicate, uh, define the value proposition, and communicate it to the right folks.

0:25:32 Got it. Yeah.

0:25:33 And like you just said earlier, the f- that fourth key question is basically our, we've got our sales and marketing arm, how do, how do we take what we've learned and what we feel like, you know, hospitals need and the problems that we can address, how do we actually communicate that effectively?

0:25:46 Um- Yeah.

0:25:48 And, and, you know, one of the things that, you know, going back to your, your earlier question about kind of the challenges that executives are facing, I mean, there's, there's existing large established sales forces out there that have been doing things well for a long time, and it's hard to, to suddenly shake that up and say, "Well, now we need to be talking to these stakeholders and be making these different types of, um, arguments a-and, and messaging."

0:26:14 And that's, that's just a, a bit of a, um, a sea change that takes some time for, for companies to transition through.

0:26:21 And, and, and, and, uh, while on that topic, um, you-- I, I presume you think you, you see that as a, as a, a, a slow transition, but, but maybe can you, can you speak to like how you see that transition actually taking place?

0:26:34 Is, is this a, is this a, um, you know, taking an, an existing, you know, sales force, you know, for example, um, kind of just focusing on sales for exa- you know, for, um, for lack of time versus marketing, but

0:26:48 a-and, and coaching them up to be better, better communicat- you know, communicators, um, or maybe sell to different stakeholders?

0:26:56 Or is that-- or do you see that transition happening where sales forces are simply reduced or replaced by, uh, folks that, um, that are maybe more proficient, um, in communicating economic value, for example?

0:27:09 Can you speak to that- No... or that topic? Y-yeah. I mean, I think it's, [laughs] I think, I think it's a little bit of, of, of all of the above. Mm-hmm. And there isn't kind of a, a single, you know, r-right solution.

0:27:21 But I think, you know, arming the, the sales organization with the right tools, and, and a lot of that is the economic tools, uh, is, is, is, is, is certainly a part of that.

0:27:34 And, and whether it's kind of, um, making changes to kind of the existing people or kind of re-retooling and rearming those same people, I, I think is kind of dependent on individual companies and, and, and [laughs] obviously individual people.

0:27:50 Yeah. Sure.

0:27:50 Um, and I-- but I do think there is an o-organizational element to this as well, where instead of having, you know, a-a-an army of kind of current traditional sales reps that are relatively kind of product focused, uh, kind of going at the same institution, um, and, and frankly often causing some frustration among the administrators and, and, and causing, um, you know, kind of confusing messages for clinicians that are getting a lot of different reps talking to them.

0:28:23 Uh, I think what we're, what we're seeing, at least from our hospital survey, is a wish for a more coordinated approach, fewer people, fewer, uh, touch points, but much higher kind of value delivered when those coordinated kind of visits are made.

0:28:39 And so you might have a single point of contact, you know, for an entire IDN or at least for, you know, kind of, um, you know, uh, key stakeholders at, at large systems that bring in specialists in, you know, health economics or product specialists or clinical specialists, you know, as needed to help address specific questions with a deeper, uh, kind of more valuable answer versus a generalist that, that is forced to try to, you know, touch a lot of different stakeholders asking for different things.

0:29:12 So I do think there's kind of some, some structural change in how the sales organizations are deployed, um, and, and some corresponding kind of, uh, uh, rearmament [laughs] of the- Yeah...

0:29:26 of the tools and, um, and, and messaging that needs to go with that. Yeah. I like that description.

0:29:32 A, uh, a kind of a retooling is probably, uh, probably what we're gonna be, uh, gonna be seeing over the next, uh, over the next several years. Yeah.

0:29:39 So using, using those four key questions as sort of the, the foundation, um, let's, let's talk about s- the kind of the, the four-step process, um, that you feel, uh, med tech companies, uh, need to embrace in order to, you know, get to that, that customer, that level of customer excellence.

0:29:58 Sure.

0:29:58 So the, the first one is, is, you know, what we call, you know, developing a deep understanding of, of customer needs, and that's, that's obviously related to understanding what problems, uh, a med tech is intending to solve- Mm-hmm...

0:30:12 for its customers. So you gotta understand your customer's needs, and that's just, you know, basic marketing 101.

0:30:18 The problem, though, is that a lot of med techs have historically, you know, spent less time on understanding customers' needs as opposed to trying to figure out ways to kind of incrementally improve products or kind of tweak the products to add additional features and functions.

0:30:34 W- you know, often independent of understanding how those might fit to customers' needs.

0:30:39 And, you know, when we talk about customer needs- Definitely don't wanna give the impression [chuckles] that hospitals are, are monolithic and all, and all have the same needs.

0:30:48 In fact, you know, there's, there's such huge variation that one of the things that we find a lot of our, our med tech clients asking for these days is understanding hospital segments and how is the right way to think about the universe of hospitals out there so that you're not kind of giving the same solution or the same messaging to a small rural hospital as you are to, uh, you know, a Mayo Clinic.

0:31:16 Uh, they just have a very different kind of set of behavioral characteristics and, uh, the need to understand how those behavioral characteristics vary and what the appropriate segments to go after, we think is an important kind of element of understanding customer needs as you're developing solutions to address those, those, those problem areas.

0:31:38 Got it. Okay. Okay.

0:31:42 The second, the second one would be around, um, kind of that optimal solution for the problem at hand, and what we call here is an inter-- this is an integrated portfolio that, you know, almost necessarily includes services that, that help make those products, uh, come to life more.

0:32:02 And, you know, a-again, this is, this is not limited to, you know, you don't have to have all of the components yourself as a med tech.

0:32:12 You might partner with, you know, a, a healthcare IT company or partner with, um, a, a, a service-focused company to help provide that.

0:32:21 But you're, you're, you're quarterbacking that delivery, pulling it together, and making it into an integrated solution that can actually address, you know, that, that need to, you know, reduce hospital-acquired infections, reduce, um, you know, readmission rates or, or whatever the problem is that you're, you're, you're targeting.

0:32:41 Okay. And, and do you, uh, do you, do you have an example of maybe what that looks like or will look like if, if, if it hasn't been-- if it's not, you know, being, being, uh, offered right now, uh, for med techs?

0:32:53 Well, I mean, that's, that's where I think the Cardiocomms and the, you know, Stryker Ascents or the BD Catto software acquisitions come into play.

0:33:00 I mean, I think you're seeing, um, you know, companies that are starting to branch out their portfolios, uh, in, in, in kind of new ways.

0:33:10 But we, LEK, are also seeing our med tech clients coming to us and saying, "Gee, you know, what about services? What can we do in services?

0:33:19 Are, are there things that we can do in procurement or inventory management or in clinical, uh, decision support systems and analytics- Okay... that, that go beyond, um, kind of just the products?

0:33:34 And, and, and what, what's the need out there? What are, what are companies that are doing these things today? How can we partner with them or potentially even acquire to, to offer that broader functionality? Got it.

0:33:45 And that's what-- that's why you mentioned, you know, maybe a, a, a big growth, um, engine, you know, looking, looking into the future is going to be health IT because so many of these, um, so many, so many of these, you know, whether, whether it's, whether it's an analytics platform or a clinical decision-making platform or some sort of economic, you know, uh, economical platform, it's gonna be largely driven by, um, by technology or by I...

0:34:08 you know, more specifically by, um, a software. Um, so that's why you-- I, I can see that you mentioned, you know, health IT is going to be big, you know, looking into the future. Yeah. Or at least data and, and data

0:34:21 analytics- Sure... which, you know, everyone knows that that's [chuckles] that's important, and that's obviously where most of the hospital spending growth is.

0:34:30 Uh, most of the spending, you know, a lot of spending has been done on developing IT systems.

0:34:36 Uh, now a lot of the money is being shifted towards how do they integrate those systems and do s-- do, um, analytics with the data that they have so that it can actually use the data, not just collect the data.

0:34:49 So, um, that kind of, um, that, that spend on healthcare IT will continue, um, uh, in the future for sure.

0:35:00 But I think the, the challenge for the med techs will be to, to, to leverage the, the data that is useful and, and help, help the hospitals convert that into something that can actually result in, um, you know, kind of improved efficiency or outcomes within the department or hospital functional areas that those med tech companies are focusing on.

0:35:22 Okay. Yep. That makes sense. Um, great. So let's, let's move on to kind of the...

0:35:28 I- is there anything else to add under this sort of-- this bullet point, um, of kind of the, the integration, the integrated portfolio and, and value-added services umbrella? No.

0:35:38 I think the next point probably brings it to life a bit more, which is around, you know, making, making very sure that that value, that the solution that you are offering is, is clearly articulated.

0:35:50 And, and it might sound obvious and, uh, easy to do, but it's shocking how rarely we see, uh, med tech companies do a good job of this.

0:36:01 Um, I mean, in, in, in most other industries, where you, you know, whenever you, you, you make a claim about your, um, you know, your, your value proposition, you often have to back it up and show it.

0:36:12 But I think in, in healthcare, it's, it's tricky. Mm-hmm.

0:36:16 Um, and, and med tech companies historically have not had the, the need to do so because the clinicians have been very happy to adopt the latest and greatest technology without really kind of putting the, the, the, you know, the pressure on to, to say, "Well, how exactly is this helping in terms of, uh, reducing our costs or improving outcomes, um, in, in non-clinical ways?"

0:36:42 So the, the bar I think is, is, is, is, is, is growing, uh, for, for med tech companies to do a better job of articulating the value proposition in economic terms.

0:36:55 Um, a good example here, we, we've, uh, we've done some work helping a client, um, that had a prefilled syringe solution, um, that would, would help, uh, hospitals in a lot of ways.

0:37:08 So everyone knows that while prefilled syringe solutions are, are good at helping reduce medication errors, they reduce some of the, uh, labor that's involved in, in preparing the, the syringes.

0:37:21 Um, they can help reduce some types of waste. Um, and there's a, you know, some other kind of smaller benefits that, that are out there.

0:37:29 But the problem was these benefits accrued to different types of stakeholders, and a lot of these benefits are just very difficult to quantify. Mm-hmm.

0:37:39 And, and, and that made it difficult for, uh, our client to be able to, you know, actually get the pharmacy directors to approve, uh, purchasing of, of prefilled syringes because the pharmacy directors really just cared about their, their budget and, and didn't care as much about some of the things that were happening outside of the pharmacy.

0:38:01 Um, and it, it required kind of a, a, a robust effort to kind of walk through the process, identify all the points in the, the workflow where medication errors can occur, what the rate of medications errors is, what type of errors could be addressed by prefilled syringes, how much direct cost those errors, uh, tend to incur, how much the indirect costs, uh, can ac- incur, and, and turning this into a clear, um, you know, economic model that actually shows how all of those different benefits that this, you know, in this case, prefilled syringes, um, could, could provide to the hospital that went well beyond just the pharmacy director.

0:38:47 And that's the type of exercise that I think med techs are gonna have to do much more consistently to show in economic terms at the end of the day why a hospital should adopt their solutions versus, uh, either staying with the status quo or, or going with someone else's.

0:39:08 Got it. Okay. Um, no, that's good stuff. That's good stuff. Let's, uh, let's, let's move on to that, that fourth, uh, that fourth step in this process. Yeah.

0:39:18 Well, and, and the, the fourth step then is j- is then just taking that kind of clearly articulated value proposition and, and turning it into, you know, the appropriate set of tools and, and documentation and knowing which people to, to share, share that with.

0:39:34 So, you know, for example, you know, even knowing at an individual hospital who, who are the right influencers. You know, is it part of an IDN? Is the decision, uh, being made at a, at a even more centralized location?

0:39:50 Um, what is the right, um, target [chuckles] to go after is, is often not as clear as it used to be, right?

0:39:58 And if, if the, if the call point in the past was the orthopedic surgeon that was in the OR, but now, you know, there's, there's more, uh, centralized decision-making, and obviously the IDNs are, are consolidating and, and, and buying up other, other hospitals.

0:40:15 So it's becoming a little bit harder to know even what-- how do you define an account? Who are the decision makers within that account?

0:40:23 And then once you, once you can answer those questions, then it's a matter of, well, who are the right people within the med tech's organization that should be calling on, on those, on those, uh, decision makers?

0:40:35 And oftentimes we're talking about pretty s- pretty senior centralized decision makers that are gonna need to see, um, uh, you know, very compelling, um, you know, arguments backed up by, you know, economic models and, and, and clear,

0:40:52 um, a, a clear [chuckles] value pr- proposition articulation that frankly is not really being, um, delivered today in, in, in many companies, so. Right.

0:41:04 You don't wanna, you don't wanna develop the value proposition but, but leave it kind of on the table or, or, or trying to share it with, with people that aren't gonna be able to, to do anything about it. Right. Yeah.

0:41:15 That, that is sort of the, the, the clear end, uh, you know, last step or end step in the process is, is taking that, that, that da- that data, that value, that message, and actually delivering it at the right time and to the, to the right people.

0:41:27 And I think, um, if I remember correctly, in leading up to this, this interview, you sent me, um, maybe a different report, and I remember reading a comment from, or maybe it was a couple comments from, um, from hospital administrators, uh, to that point of, of, you know, they have-- they've got like a lot of contacts, um, at med tech companies, but, um, but they were, you know, rather frustrated that they w- you know, they would actually prefer one contact versus, you know, versus many, for example.

0:41:54 Um- That's right. Yeah. And, and- And it, it, it goes back to the kind of, you know, the single point of contact with a, with a set of specialists- Mm-hmm...

0:42:03 versus kind of a, a kind of a generalist army that goes after, you know, primarily clinicians. Got it.

0:42:10 And that's obviously in, [chuckles] in contrast to a lot of, uh, you know, how, how, how device companies are organized and, you know, and oftentimes divided into sort of business units by, by therapeutic area.

0:42:20 But, you know, maybe, maybe that's not, uh, maybe looking into the future, that's not the best way or maybe the most effective way, um, from an organization standpoint.

0:42:29 Um, so let, let's just, let's just review 'cause, uh, there's, there's, there's a lot of really good, um, really good stuff in those four steps. Let's just review those, um, real quick.

0:42:39 So the first step would be, you know, uh, you know, have a deep understanding Of what your customers, in this case hospitals, um, need.

0:42:47 Not just physicians, but, you know, hospital, all key stakeholders basically, what they really truly need. Uh, be able to offer y- uh, offer an integrated portfolio

0:42:56 o- of products and in, in some cases complementary services. Um, being able to- Mm-hmm... you know, third, being able to, to clearly articulate, uh, you know, that, that value proposition.

0:43:08 And then, you know, lastly, um, you know, to just, to sort of, uh, not necessarily sum it up, but the, kind of the last step in the process would be making sure that you present that data and that, that, that, uh, that offering to the right, uh, to the right folks, to the right audience, uh, and the right team.

0:43:23 Is that, is that a, a decent summary? No, I think that's right. And I think, you know, for, for someone that might be outside of the med tech industry, that might sound just very, very obvious.

0:43:33 [laughs] Um, and, and perhaps to people within the med tech industry too, but again, if you, if you kind of apply, um, kind of a, a, a reasonable, um, perspective on kind of how, how med tech companies have been doing this, you know, for the last 30 years, you know, I, I think it's fair to say that these four steps are often not well executed.

0:43:56 Yeah. So understanding customer needs has not been kind of first and, and foremost.

0:44:00 Having integrated portfolios that actually kind of holistically, uh, address a problem in a, in a very kind of customer centric solution oriented manner, not often well executed.

0:44:13 Understanding and articulating the economic value proposition, very unusual and very, very rare for, for med tech companies to do that on a consistent basis.

0:44:23 And then finally, on the, on the delivering the message to the, to the right, you know, audience.

0:44:28 You know, given the changes in decision-making, it's not surprising that it's, it's hard to flip a switch and change, you know, all the relationships [laughs] that have been built up over the last, you know, few decades among the sales organizations and, and suddenly say, "Okay, now go talk to, you know, different people with a different set of needs."

0:44:45 So- Right... it's not surprising that it's kind of evolved the way it has.

0:44:50 But, you know, going back to your initial question, you know, what keeps the executives up at night in the med tech industry, I think it's how do they evolve from kind of the past state to kind of the new world and the new world and the future where, you know, these four steps are, are just gonna have to be, you know, like clockwork.

0:45:10 Right.

0:45:11 And, and it, and it almost, you know, as simple as, a- as, as simple as, as those four steps sound, um, y- you know, th- there's so many moving parts that when you actually take each step, um, and, and sort of silo it, if you will, it, you know, because of all the moving parts and the, and the, the constant change, it, it, it ac- actually gets somewhat overwhelming, um, [laughs] when you, when you, you know, kinda, kinda begin to think about, uh, uh- Yeah...

0:45:36 think about, you know, uh, um, you know, like a particular, you know, product franchise, for example.

0:45:41 And so, you know, may- I don't, I'm not sure if you would a- if you would agree with this, Jonas, but, uh, but maybe a good exercise would be if you're, if you're director over a certain product franchise within a med tech company, you know, maybe sitting down and looking at each of your, you know, your product buckets and going, uh, you know, going through this four-step process would be, you know, a great idea.

0:45:58 You know, does this product, do I really truly understand the needs that this product is, is supposedly meeting? You know, um, what other value added services could we potentially offer alongside this product?

0:46:08 You know, do, are we, are we clearly arti- articulating the value of this product and which, um- Yep... and then, and then lastly, you know, are, are we, are we presenting to the wrong audience, you know?

0:46:18 Um, do we have the right, uh, you know, the right message, uh, et cetera? So, um, yeah, I, I like, I like what you said though.

0:46:24 As, as simple as, as simple as maybe those, those sound, it, um, um, it almost, it almost, because of the, th- because there's so many moving parts, it almost is, it's a, it's a really good thing to kinda go back to those basics in a sense.

0:46:37 Yeah. Um- Yeah. Great. So, so, um, so in light of that, um, there's l- like, and, and are you, um, do you offer this, this survey? I presume you, you, you're willing to offer it to anyone who requests it, correct?

0:46:51 Yeah, no, the, the, the hospital survey that we do every year is something that we, we, we do to share with our clients and prospective clients.

0:47:00 So yeah, happy to, to share with, with that, share that with people that are interested. Yeah. So, um, and I presume may...

0:47:06 Well, or I guess let's, let's, let me ask you that before I'm, before we, uh, we move on to the, the, the next question.

0:47:12 Um, what, what's the, what i- what is the best way for, you know, folks in, folks listening to this that want to either reach out to you, uh, directly, um, or, um, or maybe want a copy of this survey, what, what would be the best, the best way to, to do that?

0:47:26 I think probably just go to the LE- Hey, Jonas? Jonas?

0:47:37 Yeah, Scott, I was just saying the best way to, to reach me [laughs] or, or LEK would be just going to the LEK website. Okay. So that's LEK.com.

0:47:49 And within that, uh, it's not hard to navigate to our med tech practice, and from there, uh, a lot of the information is, is, is in fact available in our executive insight documents, and, uh, and my contact information is in there as well.

0:48:03 Okay. So LEK, uh, dot com. I'll of course link up to that in, in the, uh, in the show notes for this interview.

0:48:09 Um, so, so in light of tho- those, that, that, that four-step process, and then, and then even, even before that, the, you know, the four key questions that we covered, um, in your opinion, what do you think, uh, you know, med tech companies need to implement like right now or immediately, uh, versus maybe something that they need at least, at the very least have on their radar, uh, you know, looking three, four, five years down the road?

0:48:34 Yeah, I mean, I, I think the thing that I would recommend is, is something that I, I get a lot of calls about, which is making sure that the current Products that, that med tech companies have, um, do in fact create economic value for their customers, um, because I think the, the bar for clinical, um, value is, is set.

0:48:59 That's just table stakes. Mm-hmm. If you can, if you can do better, that's great. But, you know, the good enough mentality is, is, is becoming pretty strong.

0:49:08 And so in order to gain traction, there is a need to show the administrators that there's an economic benefit as well. And so, um, the, the, the discipline of putting into effect in the organizations

0:49:25 a, a, a more clear articulation of that value proposition, I think, is, is, uh,

0:49:30 it's very doable because I think what will happen is, in some cases, you know, people look up, you know, in, in the mirror and see, you know what?

0:49:37 We're actually not creating a lot of value with this product or this set of products.

0:49:42 Well, that, that should, you know, raise a red flag to either kind of move to others or find ways to make the existing products, you know, actually do, do more. Mm-hmm.

0:49:54 And so, and the reason why this is particularly important is because in the next several years, we expect that hospitals are going to increasingly look for some kind of risk sharing and gain sharing arrangements with their suppliers.

0:50:12 And if you're unable to, you know, clearly understand your own economic, if you're unable to clearly understand the economic value that you're bringing to your customers, you will not be in a position to offer any sort of risk sharing or gain sharing arrangement.

0:50:29 So this is a kind of prerequisite for, uh, those types of programs which we think in the future will, um, become, you know, much more, um, much more likely.

0:50:41 I, I think that's really important, and we don't have a lot of time, but can you, can you briefly touch on that, that concept or that idea of risk sharing and gain sharing? Sure.

0:50:50 I mean, if you ask the hospitals what, what they wanna see from med tech companies in the future, uh, the thing that pops to the top of the list in terms of kind of changes from today is they wanna see more of that, more risk sharing and, um, having their suppliers take, you know, basically put their money where their [laughs] mouths are, right?

0:51:11 Yeah. And say, you know, "Hey, we're gonna, we're gonna adopt these products, but we want you to be our partner and, and share in the risks and rewards associated with, with that."

0:51:22 Um, and so there's a strong latent need from hospitals for those types of arrangements.

0:51:27 But frankly, the hospitals don't know much about what that involves other than wanting to shift some of the risk away from themselves, right?

0:51:38 And so, uh, the, the current state of risk sharing programs is very nascent, and you don't really have any good examples within the device space of, of true risk sharing arrangements that, that I've seen.

0:51:51 Um, but that's not because there isn't demand for it.

0:51:54 I think it's more because the suppliers haven't been able to figure out a way to offer it that, that actually works, um, and that has available metrics to monitor to enable kind of a, a kind of two-way win.

0:52:10 But before they can get there, again, they need to understand how much value they're creating in the first place- Right...

0:52:17 to be able to say how much they can share and how much risk they're, they're willing internally to take on. Yeah.

0:52:22 Nearly, n- yeah, nearly impossible to come up with some sort of risk, risk sharing agreement, uh, that would work without, without understanding, [laughs] clear, clearly understanding, uh, you know, the, uh, the, the economic value that you actually bring to the table.

0:52:36 That's right. Yeah. Um, no, great, great, great stuff. And I, and I, um, yeah, you still have a few minutes? Is this okay? Yeah. Okay. Yeah.

0:52:44 Re- real quick, um, I mentioned this at the beginning of the in- of the interview, but you, uh, you, you opened or co-founded, uh, LEK's Tokyo office, correct? Okay. So we're back. A slight technical difficulty there.

0:52:56 But, uh, the last question I had for you, Jonas, is, um, I believe you opened or, or co-founded the, the, the, uh, the Tokyo office for LEK. Um, can you, can you speak about that?

0:53:06 'Cause you're kind of a, a, a Midwest guy. You, you at least went to school in the Midwest. So how did you end up in, uh, over in, uh, Japan?

0:53:14 Um, it was, uh, at the time, a, an, a neat opportunity to, to spend a bit of time in Japan, and it turned into, the, the six-month project turned into a six-year, uh, stint.

0:53:26 So, um, it was, it wasn't planned, but, uh, an, an interesting path to take nonetheless.

0:53:31 Oh, I got, I got, I gotta think though that your experience over in, uh, over in Japan, um, um, is probably a huge value add that you bring to the table in terms of, uh, in terms of helping med techs though focus on their, kind of their strategies in Asia, though.

0:53:45 It, uh, I mean, Japan was, uh, was and, and still is a, a critical part of, uh, a lot of device companies', uh, you know, geographies.

0:53:55 It's been a, a large profitable market, even though it might not be growing as fast as some of the other, um, uh, Asian countries.

0:54:03 Um, but yeah, it has a, a lot of unique, uh, characteristics and challenges to, uh, to overcome to kind of tap into that opportunity.

0:54:12 So, um, you know, that was, that was something I helped a lot of our clients deal with. Got it.

0:54:18 Um, no, great stuff, and I, and I can't thank you enough for, for coming on the program and, and, and taking some time out of your schedule to, to kinda help us learn, uh, a little bit more about, uh, the insights that you gleaned from this most recent LEK hospital survey and, and, and what the, you know, what the impact is for med tech companies.

0:54:35 Uh, so thanks again for, for, for your willingness to do this. No, my pleasure, Scott. Appreciate it.

0:54:40 And for those listening who have, who have hung on this long, um, if you're, uh, if you're interested in, in, uh, listening to other MedSider interviews, uh, just go to medsider.com, um, and click on the radio button, and that will, uh, provide you with a bit, a, a couple of different links to, um, uh, to download the, all of the audio files, whether you listen to them in iTunes or Stitcher Radio or whatever, uh, whatever, um, app you prefer.

0:55:06 So, uh, check it out when you get a chance. But, um, anyway, uh, until the next episode of MedSider, everyone, take care.

0:55:15 [outro music]